LifeVantage reported second quarter revenue of $48.9 million, a 27.8% year-over-year decline and a 2.9% sequential increase from Q1. Revenue in the Americas fell 32.6%, and in Asia/Pacific & Europe it declined 2.1% (3.7% on a constant currency basis). Gross profit contracted to $36.2 million (74.0% of revenue) from $54.6 million (80.5%), driven by a $2.4 million inventory obsolescence allowance on the MindBody GLP-1 System™ and higher logistics costs. Net income per diluted share was $0.02 versus $0.19 a year ago. On an adjusted basis, EPS was $0.15 compared to $0.22, and adjusted EBITDA dropped to $3.9 million from $6.5 million. The company generated $0.5 million of operating cash in H1, down from $8.6 million, and held $10.2 million in cash at quarter end versus $20.2 million six months earlier.

During the first half of fiscal 2026 LifeVantage repurchased 44,000 shares for $0.6 million and announced a new $60 million buyback program extending through 2027. It declared a dividend of $0.045 per share payable March 16, 2026. For full-year fiscal 2026, management forecasts revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million, and adjusted EPS between $0.60 and $0.80, assuming a tax rate of 22%–24%. Guidance excludes any non-recurring expenses and reflects planned international expansion and new product launches.

After nine years at the helm, CEO Steve Fife will retire in April 2026, remaining in his role through the transition. The Board has conducted extensive succession planning and is leading an executive search to name his successor in the coming months. Raymond Greer, Board Chair, highlighted Fife’s strategic leadership in driving product innovation and operational excellence, while Fife expressed confidence in the company’s strong foundation and growth trajectory under new leadership.